Fig. 6

Regulation of the ARH3 gene Adprhl2 expression by ω-3 fatty acids and SUZ12. a SUZ12 protein expression in Pla2g6 siRNA (siPla2g6) MIN6 cells with cytokine cocktail CT2 (IL-1β + IFN-γ + TNFα) treatment (n = 5, +SD). b ChIPseq mouse (mm9) and human (hg19) data were retrieved from ChIP-atlas database (https://chip-atlas.org/peak_browser). The individual line represents independent studies reporting enrichment of SUZ12 (Green) and H3K27me3 (Pink) at ADPRHL2 transcriptional start site (TSS). c Representative western blot image and relative level of SUZ12 protein normalized to Actin post CT2 and ω-6 (arachidonic acid - AA & linoleic acid - LA) and ω-3 (eicosapentaenoic acid - EPA & docosahexaenoic acid - DHA) fatty acid treatment (n = 3–4, +SD). Ethanol (Eth) was used as solvent control for the fatty acids (FAs). d Adprhl2 mRNA expression post-CT2 and ω-3 FA (EPA and DHA) treatment (n = 3–4, +SD). e, f Suz12 and Adprhl2 mRNA expression in Min6 cells with Suz12 siRNA (siSuz12) (n = 3–4, +SD). g Re-analyzed H3K27ac ChIPseq data of CT1 (IL-1β + IFN-γ) treated Human islets [19]. *p ≤ 0.05 for A was calculated by 2wayANOVA and Šídák’s multiple comparison test, for C students’ t-test, D one-way ANOVA followed by Šídák’s multiple comparisons test, and for F & G, students’ t-test was used. Specifically, the normality and outlier test for the molecular experiment were tested using “The shapiro-Wilk test” and Dixon’s test, with a threshold of p < 0.2, respectively